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Background: RTMS has been developed as a novel tool for treating depression but the clinical 
signiﬁ  cance of this treatment has been variable, especially in the older depressed subjects.
Methods: Medication-resistant depressed patients 60 years or older were treated for two weeks 
(10 sessions) with high-frequency rTMS delivered to the left dorsolateral prefrontal cortex at 
100% of motor threshold. Each session consisted of 20 trains at 10Hz delivered in 8-second 
duration. The patients continued taking their psychotropic medications throughout the study.
Results: Nineteen of the 20 subjects completed the trial. One subject dropped out after 8 sessions 
because of discomfort. The average age of our patients was 66.8 years (6 males and 14 females). 
Six patients responded and there was a 31.6% mean reduction in Hamilton Depression Rating 
Scale (HDRS) scores from baseline at the end of the treatment. There was statistically signiﬁ  -
cant decrease from baseline in both HDRS and HARS scores at the end of treatment. rTMS 
was generally well tolerated.
Conclusion: These preliminary ﬁ  nding suggests that rTMS may be an effective treatment 
alternative to a subpopulation of medication resistant older depressed patients.
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Introduction
Major depression is a debilitating psychiatric disorder. Of all disability and premature 
loss of life in developing countries, depression accounts for 3.4% in women and 1.3% 
in men (Bland et al 1988; Bland 1996) and depression is the most common mental 
health problem in the elderly. Major depression is found in 1.7% of the elderly popula-
tion, while pervasive depression is found in 13.4% of the elderly population (Baldwin 
and Simpson 1997).
Depression in the elderly has a considerable impact on their well-being and level 
of disability (Beekman et al 2002). Late-life depression may be due to a variety of 
factors including a longstanding vulnerability, severe stress, and vascular risk. How-
ever, depression in the elderly may be more difﬁ  cult to treat than in other populations. 
Antidepressants can be administered as a ﬁ  rst line treatment; however, this can be 
problematic, as older patients often cannot tolerate dosages high enough to produce 
an antidepressant response. Predicting the antidepressant effect and side-effects of 
pharmacological treatment in the elderly can also be difﬁ  cult due to the variation in 
bioavailability. Increasing the duration of antidepressant treatment to up to 12 weeks 
in order to get a clinical response is also suggested for treatment of depression in the 
elderly population. However, this approach may be difﬁ  cult, especially in cases of 
severe depression. Antidepressant class switching and augmentation with lithium is 
another treatment option. However, this can also be problematic due to intolerable 
side-effects or potential adverse reactions with non-psychotropic medications (Baldwin Neuropsychiatric Disease and Treatment 2007:3(6) 920
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and Simpson 1997). Electroconvulsive therapy (ECT) is 
a treatment often used to treat depression in the elderly. 
Although ECT is quite effective and fast acting, it is associ-
ated with cognitive and other side-effects including nausea, 
headache and muscle aches (Datto 2000). In addition, due to 
the risks associated with anesthetic use in the elderly ECT is 
not always a viable option.
Repetitive transcranial magnetic stimulation (rTMS) 
may be another option in the treatment of late-life depres-
sion. Recently, two reviews of the evidence for the efﬁ  cacy 
of rTMS as a treatment of depression were completed; 
they focused mainly on sham-controlled studies, literature 
reviews, and meta-analysis. These separate reviews indicate 
that there is statistical evidence that rTMS is more effective 
than sham treatment, despite the small degree of clinical 
improvement (Loo and Mitchell 2005; Rachid and Bertschy 
2006). The review by Rachid and Bertschy (2006) also stated 
that rTMS treatment “is a relatively safe and well-tolerated 
technique with generally minor adverse effects such as local-
ized scalp pain, headache and neck pain”.
There have only been a few studies examining the use 
of rTMS as an antidepressant treatment in elderly patients, 
for a brief review see Table 1. Figiel and colleagues (1998) 
treated a large group of adult patients and demonstrated 
that overall 42% of patients responded to rTMS. However, 
only 23% of the elderly patients in the study responded to 
treatment, suggesting increased efﬁ  cacy of rTMS in younger 
populations as compared to elderly. The authors found the 
rTMS treatments to be well-tolerated in all patients. However, 
another recent study by Fabre et al (2004) on the effects of 
rTMS in vascular depression reported that 5 out of 11 patients 
showed a clinically meaningful improvement in Hamilton 
Depression Rating Scale scores (HDRS) (Hamilton 1960).
Another study (Mane et al 2001) found no signiﬁ  cant 
change in HDRS (Hamilton 1960) scores before and after 
rTMS treatment in depressed elderly. They also reported 
3 responders out of 10 subjects in the active treatment group 
and 3 responders out of 10 in the sham treatment group. These 
ﬁ  nding were attributed to insufﬁ  cient stimulation parameters. 
Similarly, a more recent study of rTMS as add-on treatment 
for depression in the elderly reported no additional antide-
pressant effects of real stimulation versus sham treatment. 
It was also reported that treatment with rTMS was safe, as 
adverse events were rare and the cognitive assessment dem-
onstrated no deterioration in cognitive function (Mosimann 
et al 2004).
In contrast to ECT, the beneﬁ  ts of rTMS include efﬁ  -
ciency, cost-effective administration on an outpatient basis in 
contrast to ECT, no need for anesthesia, no seizure induction 
and a lack of signiﬁ  cant cognitive side effects. rTMS may, 
therefore, be another viable option for the treatment of late-
life depression. However, the lack of consensus regarding 
the antidepressant effects of rTMS in an elderly population 
indicate there is a need for further research in this area.
The aim of this study is to establish the efﬁ  cacy and toler-
ance of repetitive transcranial magnetic stimulation (rTMS) 
for treatment of older patients with depressive disorders not 
responding to psychotropic medication.
Materials and methods
Subjects
Patients were recruited from the population served by a spe-
cialized service for mood disorders (both in and out-patients 
were included). A local ethics board approved the study and 
only patients who were able to provide written informed 
consent were included.
Inclusion criteria were: DSM-IV (American Psychiatric 
Association, 2000) criteria for depressive disorder, unipolar 
or bipolar type with a HDRS score of  18; 60 years of age 
or older and willing and capable of continuing with the same 
Table 1 Previous ﬁ  ndings of rTMS effect on depression in elderly populations
Authors N  Age  Number  %  MT  Hz  Response/outcome
   range  of  sessions     
Figiel 1998  50   22–89 (mean 60)  5  110  10  23% responded to Tx. Well-tolerated
Manes 2001  20  60.7 ± 9.8  5   80  20  No signiﬁ  cant change in HDRS scores with Tx
Mosimann 2004  24  62 ± 12  10   100  20  No addn’l antidepressant effects vs sham
Fabre 2004  11  67.9 ± 6.7  10   100  10  5 patients had clinically meaningful
            improvement in HDRS scores
Pradberg et al 1999  18  51.2 ± 16  5   90  0.3  19% decline in HDRS score for
          or 10  slow rTMS and 6% decline for fast rTMS
Nahas et al 2004  18  61.2 ± 7.3  15   114  5  35% decline over 3 weeks in HDRS score
       (103–141)
Grunhaus et al 2000  20  58.4 ± 15.7  20   90  10  27% decline over 4 weeks in HDRS scoreNeuropsychiatric Disease and Treatment 2007:3(6) 921
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medications through out the trial. Diagnosis was conﬁ  rmed 
by experienced psychiatrists on the basis of an unstructured 
clinical interview using the DSM-IV checklist (American 
Psychiatric Association 2000).
Exclusion criteria included: Personal or family history of 
epilepsy or seizure disorder, mass brain lesion, metal in the 
skull or brain, history of a head trauma, patients who were 
actively suicidal, with a concurrent serious medical illness, 
history of alcohol or drug abuse in the last 3 months.
All patients had failed to respond to treatment with at 
least two adequate trials of at least 6-weeks duration, with 
an antidepressant. All patients were required to be on stable 
medications for 6 weeks prior to commencing in the study. 
They continued taking the maximum tolerated dose of the 
last antidepressant throughout the two weeks of treatment 
with rTMS and throughout follow-up. All other psychotropic 
medications were to remain unchanged for the same period 
unless readjustments were clinically indicated.
Outcome measures
1.  Mood assessment was performed using the HDRS-21 
item, Hamilton Anxiety Rating Scale (HARS) (Hamilton 
1969) and the Beck Depression Inventory-II (BDI) (Beck 
et al 1961).
2.  Visual Analogue Scale (VAS) for depression (-D), 
anxiety (-A) and physical discomfort (-PD).
3.  The Clinical Global Impression (CGI) was completed as 
an additional scale in monitoring response to treatment.
4.  The Mini-Mental Status Exam (MMSE) (Folstein et al 
1975).
The outcome measures (HDRS, HARS, BDI, MMSE, 
and CGI) were administered at baseline (before rTMS 
treatment), mid-treatment (after 5 treatments), at the end of 
treatment (after 10 treatments), two weeks and 1 month after 
the completion of rTMS. The VAS-D, VAS-A, and VAS-PD 
were administered after each rTMS session, two weeks and 
1 month after the completion of rTMS treatment.
rTMS procedure
Patients received 10 rTMS sessions over a two-week period 
with all sessions employing the same stimulation param-
eters. A Dantec high-speed magnetic stimulator was used. A 
ﬁ  gure-8 coil was placed over the left dorsolateral prefrontal 
cortex (DLPFC) deﬁ  ned as a site 5 cm anterior to the site 
for optimal stimulation of the abductor pollicis brevis (APB) 
muscle of the contralateral side. The rTMS intensity was 
set at 100% of the motor threshold and 20 trains of 10 Hz 
stimulation with a train duration of 8 seconds were delivered 
at an intertrain interval of 52 seconds.
Results
Twenty patients were enrolled in the study, of these 
19 patients completed all 10 rTMS treatments. One patient 
completed 8 of the 10 treatments but was unable to continue 
due to local discomfort and headache. Several of the remain-
ing patients developed slight transient discomfort with the 
ﬁ  rst treatment, but none had severe or persistent pain. Of the 
20 patients, 6 (30%) were male and 14 (70%) were female, 
3 (15%) suffered from bipolar depression and 17 (85%) 
suffered from unipolar depression. The average age was 
66.8 (± 6.4) years and ranged from 60–80 years old. Fifteen 
patients were assessed at the 2-week follow-up and thirteen 
were assessed at the 1-month follow-up visit.
There was a signiﬁ  cant decrease in the mean HDRS score 
for the entire population from baseline 25.3 SD 5.8 to 17.3 
SD 6.5 after 10 treatments, p = 0.0003. There was a 31.6% 
mean reduction in HDRS from baseline. The mean HDRS 
score 1 month after the completion of treatment was found 
to be 16.6 (SD 8.7), a 34.3% mean reduction from baseline 
(Table 2).
After 10 treatments 6 patients showed a reduction in 
HDRS scores of at least 50% and another patient showed 
a reduction of at least 50% at the 1-month follow-up visit. 
Two of the 6 patients also reached remission (deﬁ  ned as a 
HDRS score  8). The patient who showed the reduction of 
50% at the 1 month follow up visit also reached remission 
at the 1 month follow up visit.
The mean HARS score at baseline was 19.3 (±8.2) and it 
reduced to 13.2 (±10.1) after 10 treatments. This is a 31.6% 
mean reduction from baseline. The mean HARS score 1 month 
after the completion of treatment was found to be 13.7 (±7.5), 
a 29.0% mean reduction from baseline (Figure 1).
Both HDRS and HARS scores showed a signiﬁ  cant 
decrease at the end of treatment (visit 10) from baseline 
(p = 0.0003 and p = 0.03, respectively).
As shown in Table 2, both the BDI and the CGI decreased 
signiﬁ  cantly at the end of treatment from baseline (p = 0.0396 
and p = 0.0088, respectively). The VAS for depression and 
anxiety did not show a signiﬁ  cant change (p = 0.117 and 
p = 0.053, respectively) with treatment. The VAS for physical 
discomfort did not show a signiﬁ  cant increase from baseline 
to the end of treatment (p = 0.336). Also the MMSE did not 
show a signiﬁ  cant change from baseline to the end of treat-
ment (p = 0.586).
Discussion
This study assessed the effect of rTMS applied to the 
left dorsal prefrontal cortex as an add-on treatment in Neuropsychiatric Disease and Treatment 2007:3(6) 922
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medication-resistant depressed patients who were 60 years 
of age or older. After two weeks (10 rTMS treatments), 30% 
(6 out of 20 patients) met response criteria ( 50% improve-
ment in HDRS), with two of these patients also meeting 
criteria for remission (HDRS   8).
This ﬁ  nding compares favorably with that of Nahas 
and colleagues (2004) who used distance adjusted TMS 
treatments in patients 65–75 years of age. In their study 
rTMS was administered for 3 weeks to the DLPFC using a 
stimulation intensity of 114% of the motor threshold (MT) 
as compared to 2 weeks at 100% of MT in our study. In 
Nahas et al 28% (5 of 18 subjects) met criteria for response; 
four of these ﬁ  ve patients had exit HDRS scores    8, and 
thus met criteria for remission. Although, our results show 
a higher number of responders to rTMS, Nahas’s study 
reported a higher number of remitters. The results of our 
study demonstrate a 31.6% mean reduction in HDRS scores 
from baseline to the end of study, increasing to 34.3% at 
one month follow up. Similarly, Nahas et al reported a 
35.2% drop on the 28-item HDRS from baseline. Finally, 
the same authors reported that 10 out of 18 subjects were 
very much improved or much improved according to the 
CGI. In our study, CGI demonstrated much or very much 
improvement in six patients.
Mosimann et al (2004) treated elderly depressed patients 
(mean age = 62 years ) with 10 daily rTMS treatments at 
100% of motor threshold, similar to our stimulation param-
eters, and reported a 20% reduction in HDRS-21 scores in 
the active treatment group. Interestingly, the sham treated 
group showed a 17% reduction in HDRS. In the Mosimann 
study, 26.6% (4 of 24) of patients receiving real TMS were 
responders, similar to the results of our study.
Previous studies found no deterioration in cognitive 
function in rTMS-treated subjects (Martis et al 2003; Speer 
et al 2001). In our study there was no evidence of cogni-
tive deterioration, as MMSE scores remained unchanged 
throughout the study. However, more rigorous cognitive 
Table 2  BDI, VAS-D, -A, -PD, CGI, MMSE scores at baseline, 
mid-treatment and 1 month follow-up
  Baseline  End of  1 month
   treatment  follow-up
BDI 31.8  ± 9.0  25.0 ± 13.3 **  24.2 ± 13.6
Visual Analog Scale       
 Depression  64.5  ± 23.3  52.2 ± 28.9  55.5 ± 38.5
 Anxiety  66.3  ± 25.6  48.7 ± 29.5  40.8 ± 39.2
 Physical  discomfort  24.6  ± 25.8  20.8 ± 26.4  36.4 ± 31.7
CGI 4.7  ± 0.7  3.9 ± 1.1**  3.1 ± 1.3 
MMSE 28.2  ± 2.3  29.1 ± 1.5  28.8 ± 1.7
Values presented as mean ± SD.
**Signiﬁ  cant decrease from baseline.
Figure 1 HDRS and HARS scores at baseline, mid-treatment, end of treatment, 2 week follow-up and 1 month follow-up.
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tests are needed to conﬁ  rm the absence of deterioration in 
cognitive functioning.
Mosimann et al (2004) found rTMS to be a safe treat-
ment with none of the patients withdrawing from the study 
or reporting serious adverse effects. One patient in our 
study withdrew, after 8 sessions, because of discomfort and 
headaches.
This is similar to the study by Su et al (2005) where 3 out 
of 30 patients dropped out of the treatment because of pain 
or worsening of clinical symptoms. As well, four patients 
in the active and two patients in the sham group reported 
headaches, which is consistent with complaints reported by 
our study subjects.
The response rate obtained by most other studies are quite 
similar to our data, although in contrast to Su et al (2005) 
who found no responder in patients older than 55 years of 
age. In our study we did not ﬁ  nd any signiﬁ  cant difference 
in age, sex, or degree of cognitive impairment between 
responders and non-responders. In addition, responders and 
non-responders did not differ in severity of depression, as 
measured by initial HDRS scores or number of previous 
antidepressant treatments.
It has yet to be established if rTMS’s antidepressant 
response rates differ between elderly and younger popula-
tions of patients with depression. Published reports indicate 
a lower antidepressant effect of rTMS in elderly depressed 
patients as compared to younger populations (Figiel et al 
1998; Pradberg et al 1999; Su et al 2005). Fregni et al 
(2006) found age and treatment refractoriness to be signiﬁ  -
cant negative predictors of depression improvement. They 
reported that TMS antidepressant therapy in younger and less 
treatment resistant patients resulted in better outcomes. The 
ﬁ  ndings in our study of a response rate of 31.6% after only 
10 daily sessions of rTMS at 100% of MT is comparable to 
the response rates of 30% and 35% respectively reported 
by Garcia-TORO et al (2001) and Fitzgerald et al (2003) in 
younger adults.
Two more recent studies reported similar response rates 
after treating younger adults at higher intensities and for lon-
ger sessions. Response rate of 30% was reported by Isenberg 
et al (2005) who gave 4 weeks of high frequency rTMS; and 
Avery et al (2006) found a 32% response rate when rTMS 
was administered for 15 sessions at an intensity of 110% of 
MT. Although, we administered rTMS for 10 sessions at 
an intensity of 100% MT, it appears that our older patients 
responded well.
Rossini et al (2005), who reported a response rate of 
61%, argued that treatment response was unrelated to the 
demographic and clinical characteristics of their patients. 
Fitzgerald et al (2006) have also reported no relationship 
between age and response to rTMS treatment. In addition, 
it is of interest to note that Jorge et al (2004) reported that 
reduction of depression symptoms in rTMS treated post 
stroke patients was not inﬂ  uenced by the patient’s age or 
type or location of ischemic strokes.
The limitations of this study require some consideration. 
This is non-controlled, open study with a small sample size. 
This is a signiﬁ  cant limitation, which likely restricted the 
statistical power. Our patients all received antidepressants 
during the trial. We ensured that all patients stayed on a stable 
dose of the current medications for at least six weeks before 
commencement of rTMS, during the trial and follow-up 
period. However, changes to psychotropic medications 
(excluding antidepressants) were allowed, throughout the 
study, where clinically indicated. Since the study lacks a 
control group we cannot exclude the possibility of a placebo 
effect. The response to rTMS seen in our study may be due 
to a placebo effect of a cutting edge treatment, but given 
that all of our subjects had been taking stable doses of the 
same medication for at least six weeks, were not improv-
ing before the trial and had a high degree of resistance, this 
is unlikely. Khan et al (2002) reported that more severely 
depressed patients responded poorly to placebo compared 
to antidepressant treated subjects.
Recently, it has been suggested that 10 treatments and 
100% of MT may not be sufﬁ  cient to produce a maximum 
response. But our study was planned and started a few years 
ago when routine rTMS treatment was a course given for two 
weeks. Thus, administration of a ﬁ  xed number (10) of rTMS 
sessions may have reduced the efﬁ  cacy of our treatment as a 
higher number of sessions optimized the clinical beneﬁ  t of 
treatment as demonstrated in some recent studies (Janicak 
et al 2002; Grunhaus et al 2003; Rossini et al 2005). However 
the literature is lacking a study that directly compares the 
effects of 2 different numbers of pulses per day on mood. 
More rTMS sessions even at higher stimulation intensity 
have not consistently produced better clinical outcome as 
reported in newer studies (Isenberg et al 2005; Avery et al 
2006). Rossini et al (2005) suggested that methodological 
factors might be responsible for the variable results reported 
in the literature.
In conclusion, rTMS is a safe and well-tolerated treatment 
and may be a useful adjunctive treatment to medications in 
elderly treatment resistant depressed patients. We believe 
our ﬁ  ndings add to the growing body of literature that 
suggests the effectiveness of rTMS. Despite the fact that Neuropsychiatric Disease and Treatment 2007:3(6) 924
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the generalizabilty of our study ﬁ  ndings are limited, rTMS 
treatment in older depressed population is showing encourag-
ing results and requires further study.
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